Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753204 | 1.00 | GPR119 (0.41) | GPR119KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL3745483 | 0.87 | NPC1 (0.42) | GPR119KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL3116317 | 0.84 | MEN1 (0.40) | GPR119KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL3116309 | 0.84 | MEN1 (0.40) | GPR119KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL3119390 | 0.84 | MEN1 (0.40) | GPR119KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL2389377 | 0.83 | ALDH1A1 (0.45) | GPR119KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL2446754 | 0.83 | ALDH1A1 (0.43) | GPR119KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL2444180 | 0.83 | KDM4E (0.39) | GPR119KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL2444183 | 0.83 | KDM4E (0.39) | GPR119KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL282240 | 0.82 | GPR119 (0.60) | GPR119KMT2AMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | GPR119 672/4885KDM4E 3910/4885ALDH1A1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.